Oculis' (OCS) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Oculis' stock has been reaffirmed a "sell (D-)" rating by Weiss Ratings, reflecting negative sentiment toward the company's performance.
• Despite the sell rating from Weiss, other analysts like Needham & Company and Chardan Capital have issued "buy" ratings with price targets as high as $51.00, indicating mixed opinions on the stock's future.
• The company reported a quarterly loss of $0.59 EPS, missing analysts' expectations, with revenue slightly exceeding forecasts at $0.25 million.

Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently weighed in on OCS. Needham & Company LLC initiated coverage on Oculis in a report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 price target for the company. Chardan Capital upped their price target on Oculis from $33.00 to $51.00 and gave the stock a "buy" rating in a report on Wednesday. Wall Street Zen cut Oculis from a "hold" rating to a "sell" rating in a report on Sunday, September 21st. Finally, HC Wainwright upped their price target on Oculis from $33.00 to $36.00 and gave the stock a "buy" rating in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $41.00.

Oculis Stock Up 4.2%

OCS opened at $19.87 on Wednesday. The firm has a 50 day moving average price of $17.58 and a 200 day moving average price of $18.08. The company has a market cap of $867.56 million, a PE ratio of -7.44 and a beta of 0.29. Oculis has a 1 year low of $14.00 and a 1 year high of $23.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). The business had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%. Sell-side analysts expect that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

Several institutional investors and hedge funds have recently made changes to their positions in the company. Kestra Private Wealth Services LLC acquired a new stake in Oculis in the first quarter worth $234,000. Bosun Asset Management LLC acquired a new stake in Oculis in the second quarter worth $378,000. Marshall Wace LLP acquired a new stake in Oculis in the second quarter worth $393,000. Bank of America Corp DE increased its position in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after buying an additional 10,667 shares during the period. Finally, Geode Capital Management LLC increased its position in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock worth $571,000 after buying an additional 6,384 shares during the period. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.